Literature DB >> 17426712

Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease.

J L Howarth1, S Kelly, M P Keasey, C P J Glover, Y-B Lee, K Mitrophanous, J P Chapple, J M Gallo, M E Cheetham, J B Uney.   

Abstract

We studied the ability of heat shock, DnaJ-like-1 (HSJ1) proteins (which contain DnaJ and ubiquitin-interacting motifs) to reduce polyglutamine-mediated inclusion formation. The experiments demonstrated that expression of heat shock protein 70 (hsp70), hsp40, HSJ1a, and HSJ1b significantly reduced protein inclusion formation in a model of spinal and bulbar muscular atrophy (SBMA). HSJ1a also mediated a significant decrease in the number of inclusions formed in a primary neuronal model of protein aggregation. Studies to elucidate the mechanisms underlying these reductions showed that hsp70 and hsp40 increased chaperone-mediated refolding. In contrast, expression of HSJ1 proteins did not promote chaperone activity but caused an increase in ubiquitylation. Furthermore, HSJ1a was associated with a ubiquitylated luciferase complex, and in the presence of HSJ1a but not an HSJ1a UIM mutant (HSJ1a-deltaUIM) there was a reduction in luciferase protein levels. Together these results show that HSJ1 proteins mediated an increase in target protein degradation via the ubiquitin-proteasome system (UPS). We also found that the expression of HSJ1a significantly decreased the number of neurons containing inclusions in an in vivo model of polyglutamine disease. These findings indicate that targeted modification of the UPS to facilitate degradation of misfolded proteins may represent a highly effective therapeutic avenue for the treatment of polyglutamine disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426712     DOI: 10.1038/sj.mt.6300163

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

Review 1.  Therapeutic approaches to spinal and bulbar muscular atrophy.

Authors:  Srikanth Ranganathan; Kenneth H Fischbeck
Journal:  Trends Pharmacol Sci       Date:  2010-09-20       Impact factor: 14.819

Review 2.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

Review 3.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

Review 4.  Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases.

Authors:  Herman van der Putten; Gregor P Lotz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

5.  DNAJB2 expression in normal and diseased human and mouse skeletal muscle.

Authors:  Kristl G Claeys; Magdalena Sozanska; Jean-Jacques Martin; Emmanuelle Lacene; Ludivine Vignaud; Daniel Stockholm; Pascal Laforêt; Bruno Eymard; Antoine Kichler; Daniel Scherman; Thomas Voit; David Israeli
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

Review 6.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 7.  The Role of the Protein Quality Control System in SBMA.

Authors:  Paola Rusmini; Valeria Crippa; Riccardo Cristofani; Carlo Rinaldi; Maria Elena Cicardi; Mariarita Galbiati; Serena Carra; Bilal Malik; Linda Greensmith; Angelo Poletti
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

8.  Identification of a Large DNAJB2 Deletion in a Family with Spinal Muscular Atrophy and Parkinsonism.

Authors:  Elena Sanchez; Hossein Darvish; Roxana Mesias; Shaghyegh Taghavi; Saghar Ghasemi Firouzabadi; Ruth H Walker; Abbas Tafakhori; Coro Paisán-Ruiz
Journal:  Hum Mutat       Date:  2016-08-21       Impact factor: 4.878

9.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

10.  HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease.

Authors:  Joanna L Howarth; Colin P J Glover; James B Uney
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.